ClinicalTrials.gg
RecruitingNCT06111976TraumaStimUpdated May 8, 2024

Repetitive Transcranial Magnetic Stimulation Plus Reactivation Therapy Efficacy on PTSD Symptom Severity in Resistant PTSD

An interventional study of Repetitive Transcranial Magnetic Stimulation (rTMS) and Placebo in Post Traumatic Stress Disorder, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Stress Disorders, Post-Traumatic by Assistance Publique - Hôpitaux de Paris — 7 open to participants now, 7 under way, none of them phase 3. Stress Disorders, Post-Traumatic · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
8th of 12
102 · median 265
Started
2024
the only one that year
No phase
9 of 22
3 open now
Registered
16th of 22
by date

Among the 22 studies in Stress Disorders, Post-Traumatic by Assistance Publique - Hôpitaux de Paris, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2024, is one of 9 with no phase, and was the 16th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

7 of the 22 studies in Stress Disorders, Post-Traumatic by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Stress Disorders, Post-Traumatic by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

A French multicenter randomized and double blinded shamed controlled study recruiting patients who present resistant PTSD. The aim of this trial is to assess the efficacy of cerebral modulation by rTMS with simultaneous reactivation of traumatic memory on the PTSD symptoms at M1.

Read the detailed description

Detailed Description : PTSD is considered as one of the top 10 public health concerns. Most patients with PTSD receive pharmacologic treatment and traumatic reactivation therapy. However, to date, the optimal treatment alternatives for non-responders PTSD patients are unknown.

Functionally, the metabolic activity of the prefrontal-amygdala cortex circuit in PTSD is significantly altered. Repetitive Transcranial Magnetic Stimulation (rTMS) provides focused, non-invasive stimulation of cortical areas of the central nervous system and could correct cortical defective activation of the prefrontal cortex seen in PTSD Patient (FDA has already approved rTMS for depression and acoustic-verbal hallucinations treatment).

Pairing rTMS with cues relevant to the trauma may be a novel approach to treat PTSD patient.

The study will enroll 102 subjects with resistant PTSD. After screening and inclusion phase, the treatment phase with 12 sessions of rTMS and simultaneous reactivation of traumatic memory or sham rTMS and simultaneous reactivation of traumatic memory will be performed (3 to 4 weeks). Antidepressant treatment will be maintained. The follow up phase consist of 3 visits at M1, M3 and M6 to follow the evolution of the PTSD symptoms.

03

Conditions studied

  • Post Traumatic Stress Disorder

Keywords

  • Stress Disorders
  • Traumatic Stress Disorders
  • Post-Traumatic Trauma and Stressor Related Disorders
  • Mental Disorders
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged between 18 and 65 years.
  • Presenting a PTSD according to criteria
  • Patient with persistent symptoms (PCL-5>40) after a 6 weeks treatment with labelled antidepressant for PTSD (paroxetine or sertraline)
  • Patient with health insurance (AME excepted)
  • Signed written inform consent

Exclusion criteria

Exclusion Criteria :

  • for rTMS:

    • History of epilepsy or seizure
    • Cochlear implants
    • Cardiac pacemaker or intracardiac lines, or metal in the body
  • Patient has already had a rTMS session and/or Electroconvulsive therapy (ECT) and/or Transcranial direct current stimulation (tDCS)
  • Ongoing PTSD-oriented cognitive-behavioral therapy
  • Lifetime psychotic or bipolar disorder or antisocial personality or borderline personality
  • Brain injury defined by medical report (including cortical and subcortical atrophy, dementia, stroke, and head trauma)
  • Current substance dependence (including alcohol, excluding tobacco);
  • Acute suicidal ideation
  • No adequate mastering of the French language or no ability to consent
  • Pregnancy (confirmed by a urine test beta-HCG) or breast feeding or absence of
  • Patient under legal protection measure and or deprived of freedom
  • Participation in any other interventional study or in the exclusion period any other interventional study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    rTMS with simultaneous reactivation of traumatic memory in resistant PTSD

    rTMS with simultaneous reactivation of traumatic memory in resistant PTSD during 12 sessions (3 to 4 weeks)

    Procedure: Repetitive Transcranial Magnetic Stimulation (rTMS)

  • Placebo comparator
    sham rTMS and simultaneous reactivation of traumatic memory in resistant PTSD

    sham rTMS and simultaneous reactivation of traumatic memory in resistant PTSD during 12 sessions (3 to 4 weeks)

    Procedure: Placebo

Interventions

  • ProcedureRepetitive Transcranial Magnetic Stimulation (rTMS)

    rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions. A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions.

  • ProcedurePlacebo

    sham rTMS with simultaneous reactivation of traumatic memory will be performed 3 to 4 times a week for 3 to 4 weeks through 12 sessions. A traumatic script will be prepared by the patient at the inclusion visit, which will be used to reactivate the traumatic memory after every rTMS or sham rTMS sessions.

06

What researchers measure

Primary outcomes

  1. PTSD severity score measured at M1 after 12 sessions of rTMS or sham rTMS and simultaneous reactivation of traumatic memory

    CAPS-5 total severity score at M1 post treatment will be compared between groups (cerebral modulation by rTMS with simultaneous reactivation of traumatic memory VS sham rTMS with simultaneous reactivation of traumatic memory)

    Time frame: Month 1 after 12 sessions of rTMS

Secondary outcomes

  1. PTSD severity scores at M3 and M6 measured with CAPS-5

    The different dimensions of PTSD (assess by CAPS-5): Severity, repetition, avoidance, neurovegetative activation at M3 and M6 post treatment

    Time frame: At inclusion (v1), Month 3 and Month 6 post treatment

  2. The severity of PTSD assessed by PCL-5 at each visit.

    PTSD severity score measured with the PTSD Checklist (PCL-S self-questionnaire) at once a during TMS sessions, M1, M3 and M6 post treatment

    Time frame: at once a during TMS sessions, Month1, Month 3 and Month 6 post treatment.

  3. Dissociative symptoms severity scores (1)

    Dissociative symptoms severity score measured with the Clinician Administered Dissociative States Scale (CADSS)

    Time frame: at inclusion (V1), up to 4 weeks (V13) (end of treatment), Month 1, Month 3, Month 6 post treatment

  4. Dissociative symptoms severity scores (2)

    The Multidimensional Assessment of Interoceptive Awareness (MAIA)

    Time frame: at inclusion (V1), up to 4 weeks (V13) (end of treatment), Month 1, Month 3, Month 6 post treatment

  5. Dissociative symptoms severity scores (3)

    The Dissociative Experiences Scale (DES)

    Time frame: at inclusion (V1), up to 4 weeks (V13) (end of treatment), Month 1, Month 3, Month 6 post treatment

  6. The severity scores of the dimensions of anxiety at V13 (end of treatment), M1, M3, M6 post treatment.

    The severity scores of the dimensions of anxiety measured with HAM-A at V13 (end of treatment), M1, M3 and M6.

    Time frame: Up to 4 weeks (V13) (end of treatment), Month 1, Month 3, Month 6 post treatment.

  7. Symptoms of depression at V13 (end of treatment), M1, M3, M6 post treatment.

    The severity scores of the dimensions of depression measured with HAM-D at V13 (end of treatment), M1, M3 and M6.

    Time frame: at V13 (end of treatment), Month 1, Month 3, Month 6 post treatment.

  8. Evolution of social cognition at M3 post treatment.

    Evolution of social cognition at M3 post treatment by a neuropsychologist

    Time frame: at Month 3 post treatment

  9. Quality of life

    Quality of life evolution post treatment and M6 assessed by WHOQOL EuroQol Health Measure

    Time frame: post treatment and Month 6

  10. Quality of life

    Quality of life evolution post treatment and M6 assessed by EQ-5D-5L

    Time frame: post treatment and Month 6

  11. Proportion of adverse events during the active treatment phase and during the follow-up

    Number and description of adverse events during the active treatment phase and during the follow-up

    Time frame: through study completion, up to 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jul 2026, 28 months after the start.

Of 1,066 non-industry interventional studies with no phase under Stress Disorders, Post-Traumatic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 28 months is below that.

Counting every sponsor, half of 1,094 studies reached it within 35 months; a quarter within 17 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2023
First posted
Nov 1, 2023
StartActual
Mar 7, 2024
Primary completionEst.
Jul 7, 2026
CompletionEst.
Oct 7, 2026
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06111976
Responsible party
Sponsor
First posted
Nov 1, 2023
Start date
Mar 7, 2024
Primary completion
Jul 7, 2026 (estimated)
Completion
Oct 7, 2026 (estimated)
Last update
May 8, 2024

Study contacts

Florian FERRERI, MD, Ph
Contact
florian.ferreri@aphp.fr
+33149282635
Florian FERRERI, MD, ph
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion